search for




 

Long-term Treatment Outcomes of Intravitreal Bevacizumab Treatment for Myopic Choroidal Neovascularization
근시 맥락막신생혈관에 대한 유리체내 베바시주맙 치료의 장기 결과
JKOS 2019 Jun;60(6):547-54
Published online June 15, 2019;  https://doi.org/10.3341/jkos.2019.60.6.547
Copyright © 2019 The Korean Ophthalmological Society.
PDF Download Count: 95 / View Count: 92

Jeong Min Lee, MD, Jong Woo Kim, MD, Dong Won Lee, MD, Jae Hui Kim, MD
이정민·김종우·이동원·김재휘

Department of Ophthalmology, Kim’s Eye Hospital, Konyang University College of Medicine, Seoul, Korea
건양대학교 의과대학 김안과병원 안과학교실
Received November 29, 2018; Revised February 3, 2019; Accepted May 16, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Purpose: To evaluate the long-term treatment outcomes of bevacizumab therapy in patients with myopic choroidal neovascularization (CNV).
Methods: A retrospective review was performed of medical records regarding 43 eyes with myopic CNV that were treated with intravitreal bevacizumab injection. Visual acuity at diagnosis was compared with that measured at the final follow-up; the incidence and timing of re-activation were evaluated. In addition, factors associated with final follow-up were analyzed.
Results: Mean patient age was 39.3 ± 12.9 years and mean spherical equivalent (SE) was -11.9 ± 4.4 diopters. Patients were followed- up at a mean of 42.1 ± 17.0 months. Re-activation of the lesion was noted in 17 eyes (39.5%). The mean time to first re-activation was 19.5 ± 15.4 months from the time that resolution of subretinal fluid/retinal fluid was confirmed after initial treatment. The mean visual acuity (the logarithm of the minimal angle of resolution) was 0.40 ± 0.25 at diagnosis and 0.26 ± 0.31 at the final follow-up. Visual acuity at the final follow-up was significantly improved when compared with the baseline value (p = 0.005). Patient age (p < 0.001), SE (p = 0.003), and visual acuity at diagnosis (p < 0.001) were significantly associated with visual acuity at the final follow-up.
Conclusions: Bevacizumab therapy was a useful method for long-term treatment of myopic CNV. The observation of relatively late re-activation after the initial treatment suggests a need for continuous long-term follow-up.
Keywords : Bevacizumab, Choroidal neovascularization, Myopia

 

October 2019, 60 (10)